ECZACIBAŞI-MONROL
Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) is delighted to announce that it has reached an agreement in principal with FutureChem based in Seoul, South Korea, a radiopharmaceutical company, for the clinical supply of radioisotope, Lu-177 n.c.a. (Lutetium-177 non-carrier-added), to support FutureChem’s Investigational New Drug IND-enabling Phase 2 clinical trial with Ludotadipep, 177Lu-FC705 to assess the efficacy and safety for repeated administration of the recommended Ludotadipep dose in patients with metastatic castration resistant prostate cancer (mCRPC). Clinical supply contract signed by two parties on 18th of Oct 2022 in Barcelona. A new supply contract between Monrol and FutureChem will be signed following the commercialization of the product in South Korea and US.
Monrol General Manager Aydın Küçük, added: “We are delighted to be working with FutureChem to have a clinical supply agreement to support clinical development program of an innovative radiopharmaceutical product Ludotadipep, 177Lu-FC705 to assess the efficacy and safety in patients with metastatic castration resistant prostate cancer (mCRPC). Collaboration with FutureChem is another example of we continue our mission to improve quality of life for cancer patients and transform patient care for the future.”
Dae Yoon Chi, Chief Executive Officer, FutureChem said: “FutureChem is thrilled to be partnering with Monrol, a company with a broad set of offerings to support our development programs and pipeline. We look forward to rolling out the supply of high-quality radioisotopes to our Phase 2a clinical trial patients in US soon. We have a future prospect to expand this partnership, supply of radioisotope, Lu-177 n.c.a. by Monrol for the commercialization of the Ludotadipep, 177Lu-FC705”.
ENDS
About Monrol
Monrol is one of the world’s largest nuclear medicine companies leading innovation for the development and manufacturing of GMP grade radioisotopes and radiopharmaceuticals having headquarters in Istanbul. Monrol is distributing its world-class radiopharmaceutical products portfolio with excellence in global markets. Monrol is a CDMO, providing early development support to its customers as well as offering fully integrated services for today’s nimble, lean, virtual companies effectively taking new product concepts into clinical trials, demonstrating proof of concept and going into first-in-human studies. Monrol is committed to transform and improve patient journey in cancer treatment with its radiopharmaceutical products portfolio distributing to more than 50 countries around the globe. To learn more, visit www.monrol.com and LinkedIn.
About FutureChem
Since its establishment in 1999, FutureChem has led the radiopharmaceuticals industry through research and development. FutureChem is the global forerunner in the production of radiopharmaceutical precursors and compounds, development of remarkable radiopharmaceuticals, and worldwide commercialization of new medicine.
FutureChem developed competitive technologies and innovative products with a mission to grow the company into a world-class radiopharmaceuticals enterprise, so to contribute a healthy and happy society, protecting the health of patients.
For more information, please visit www.futurechem.co.kr
About FC705 and 177Lu-FC705
2nd generation PSMA-targeted therapeutic radiopharmaceuticals. 177Lu-FC705 belongs to the 2nd generation of albumin binders introduced drugs. Its hydrophilicity is higher than that of other compounds, and has low nonspecific binding. 177Lu-FC705 will have constantly increasing uptake in prostate cancer due to the introduction of albumin binder while it will be rapidly excreted from normal organs. In this regard, 177Lu labeled 177Lu-FC705 can be expected to have high therapeutic effect and very low damage to normal organs. Currently, efficacy of 177Lu-FC705 is being clinically tested in Phase 2 in Korea and 1/2a in US.
About n.c.a. Lutetium-177
Lutetium-177 n.c.a is a radioisotope of choice for targeted radionuclide therapy. Lu-177 n.c.a production process enables treatment options that have the potential to improve treatment outcomes for certain cancer patients today and more potential treatment options in future under clinical development. The unique properties of Lu-177 n.c.a. make it a theranostically desirable radioisotope for peptide receptor radionuclide therapy (PRRT) to treat certain cancers like Neuro Endocrine Tumors (NET) and Prostate cancer. N.c.a. Lutetium-177 DMF by Monrol listed by FDA.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221118005260/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIKE, Inc. Announces New Geography Leadership Appointments20.1.2026 22:15:00 CET | Press release
NIKE, Inc. (NYSE: NKE) today shared the following note with teammates regarding changes to its Senior Leadership Team: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120575539/en/ César Garcia, VP/GM Nike Europe, Middle East and Africa (EMEA) To: Lst-Global From: EHill Subject: Leadership Announcements Team, In recent months, the Senior Leadership Team has benefited from having our Geography VP/GMs at the table helping us move faster and bringing us closer to athletes* in both countries and marketplaces around the world. As we continue to drive our Win Now actions and stand up our Sport Offense, I’d like to share several important leadership changes across three of our Geo VP/GM roles. EMEA Carl Grebert, a true legend on our team, has decided to retire after nearly 30 years of service and leadership across global, country and geography roles across the company. Carl shared his thinking with me some time ago, and I’m deepl
Xsolla Expands Payment Coverage in Portugal With MB Way, a Leading Mobile Wallet Trusted by 6 Million Customers, to Unlock New Growth Opportunities for Game Developers20.1.2026 16:41:00 CET | Press release
Empowering Portuguese players with Seamless, Localized Payment Options for a Smoother and More Trusted Gaming Experience Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced the expansion of its payments solution in Portugal with the addition of MB Way. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120938007/en/ Graphic: Xsolla Portugal is a leader in digital transformation, with nearly 90% of its population online, high smartphone usage, and a strong adoption of mobile banking. Trusted by 6 million people, connected to 11 million cards, supported by 28 banks, and driving 496 million transactions in 2024, MB Way provides 95% market coverage, allowing most bank customers to use the service. MB Way is the leading mobile wallet in Portugal, with an estimated market share of 34%-45% of all e-commerce transactions locally. By adding MB Way as a payment meth
Balena Secures Strategic Growth Investment to Accelerate Edge AI and IoT Fleet Management20.1.2026 15:14:00 CET | Press release
New partnership fuels product innovation and reinforces Balena’s position as the leading hardware-agnostic platform dedicated to the security and long-term stability of device fleets Balena, the leading platform for deploying, managing, and scaling fleets of edge computing and AI devices, today announced a strategic growth investment from LoneTree Capital (“LoneTree”), a New York-based growth capital firm. The partnership will accelerate Balena’s product innovation with a focus on Edge AI workloads and security features to meet evolving compliance needs, while expanding resources for customer success and global fleet support. Founded in 2011, Balena enables customers to leverage the ever-increasing power of technology to solve real-world problems by providing software to manage the full lifecycle of edge computing devices. The platform abstracts away infrastructure complexity, handling critical tasks like secure Over-The-Air (OTA) updates so engineering teams can focus on their core pr
SIRBAI Launches Middle East’s First AI-Powered Autonomous Drone Swarm Technology at UMEX 202620.1.2026 15:11:00 CET | Press release
New platform enables coordinated, autonomous drone operations designed for modern defense environments SIRBAI today announced the official launch of the Middle East’s first AI-powered autonomous drone swarm technology at UMEX 2026 - a global exhibition platform for unmanned systems and autonomous capabilities - marking the company’s entry into the defense technology sector. Designed for unmanned aerial systems (UAS), the platform enables multiple drones to operate collaboratively with a high degree of autonomy, even in complex and contested environments. As the first company in the region to offer this advanced capability, SIRBAI is set to redefine the modern battlefield with innovative and scalable autonomous technology, establishing new standards for resilient and operator-friendly mission systems for modern defense operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120186459/en/ SIRBAI Launches Middle East’s Fi
FlightSafety International Receives EASA and UK CAA Certification for Gulfstream G700 Flight Simulator at Farnborough Learning Centre20.1.2026 15:05:00 CET | Press release
Certification advances training support and builds on FlightSafety’s decades-long partnership with Gulfstream Aerospace Corp. FlightSafety International Inc. (FSI), a global leader in aviation training and simulation technology, announced today it has received European Union Aviation Safety Agency (EASA) and UK Civil Aviation Authority (CAA) certification for its Gulfstream G700 Full Flight Simulator (FFS), located at the company’s Farnborough Learning Centre. The certification of the simulator, which was engineered and manufactured by FSI, validates the advanced technology, accuracy, and fidelity of the flight training device, confirming it meets the highest European and UK regulatory standards. The FFS will be leveraged for initial, recurrent, and advanced pilot training to support G700 and Gulfstream G800 aircraft, further expanding global access to high-fidelity training. “The G700 simulator certification in Farnborough reinforces FSI’s long-standing commitment to supporting Gulfst
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom